NRC Form 374
(8-82)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 06

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93–438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Stillwater Medical Center Nuclear Medicine Service	In accordance with letter dated January 10, 1985
2. 1323 West 6th Avenue Stillwater, Oklahoma 74074	3. License number 35-16149-01 is amended in its entirety to read as follows:
	4. Expiration date April 30, 1985
	5. Docket or Reference No. 030-10495

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2.5 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	C. Any	C. 3 millicuries of each byproduct material authorized in Subitem 6.C.

8506120255 850528
REG4 LIC30
35-16149-01 PDR

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
35-16149-01
Docket or Reference number
030-10495

Amendment No. 06

D. Iodine-131	D. Any iodine that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State Regulations.	D. 250 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. In vitro studies

D. For treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma.

CONDITIONS

10. Licensed material shall be used only at Stillwater Medical Center, 1323 West 6th Avenue, Stillwater, Oklahoma.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
35-16149-01
Docket or Reference number
030-10495
Amendment No. 06

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

James A. Waltermire, M.D.	Groups I, II, and III In vitro studies Iodine-131 as iodide for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma
Phillip G. Russell, M.D.	Groups I, II, and III In vitro studies Iodine-131 as iodide for treatment of hyperthyroidism
John Bolene, M.D.	Groups I, II, and III In vitro studies Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

14. Patients containing iodine-131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.

15. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

A. Has the prior written permission of the hospital's administrator and its Radiation Safety Committee, and

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
35-16149-01
Docket or Reference number
030-10495

Amendment No. 06

15. (continued)

B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem A above and of the license(s) specified in Subitems B and C above. These records shall be maintained for 5 years from the time the licensee grants its permission under Subitem A above.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. The licensee may use the Calicheck device for doing linearity tests of his dose calibrator provided he follows the procedures in the Calcorp, Inc., Manual dated March 2, 1982.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
35-16149-01

Docket or Reference number
030-10495

Amendment No. 06

18. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated May 4, 1979, and letters dated September 8, 1980, December 18, 1980, November 28, 1983, and January 10, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION
Original Signed By
Jack E. Whitten

Date MAY 28 1985

By _____
Nuclear Materials Safety Section
Region IV
Arlington, Texas 76011

Official Record Copy

1/1 ML40